Skip to content

Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper Rash Prophylaxis

A Clinical Observation to Assess the Safety and Consumers' Satisfaction of Moussik vs Desitin Creamy Ointment in Prophylaxis of Diaper Rash. A Single Blind, Multicenter, Randomized, Cross-over Study

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01167465
Enrollment
0
Registered
2010-07-22
Start date
2013-01-31
Completion date
2013-12-31
Last updated
2014-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diaper Rash

Keywords

Diaper Dermatitis, Diaper Rash, Erythema

Brief summary

The purpose of this clinical observation is to evaluate the safety and consumers' satisfaction of Moussik vs Desitin Creamy ointment as a diaper rash protection product.

Interventions

OTHERMoussik Diaper Rash Mousse

To be used as instructed

OTHERDesitin Creamy Ointment

To be used as instructed

Sponsors

Trima, Israel Pharmaceutical Products
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
3 Months to 18 Months
Healthy volunteers
Yes

Inclusion criteria

* Healthy male or female infants aged between 3-18 months who are routine users of disposable diapers

Exclusion criteria

* Children with symptoms of systemic disease or skin lesions. * Children diagnosed as having diaper dermatitis at baseline * Known hypersensitivity to any of the components of the trial preparations. * Children suffering from atopic diseases. * Children who have participated during the last month in another clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Six point erythema skin gradeAfter two weeks0 - Normal skin \+ - Questionable erthema not covering entire area 1. \- Definite erythema 2. \- Erythema and induration 3. \- Vesiculation 4. \- Blister reaction

Secondary

MeasureTime frame
Visual analogue scale (VAS) from 0 to 10After two weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026